Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1531 to 1540 of 2575 total matches.
Oxycodone OxyContin
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
to morphine has ranged from 0.7 to 1.5. Parenteral oxycodone is 10 to
12 times as potent as codeine. Oral ...
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Arrhythmias From Droperidol?
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002 (Issue 1132)
anesthesiologists consider droperidol in doses of 0.625-1.25 mg IV
the drug of choice for patients at high risk ...
The FDA has added a "black box" warning about the risks of QT prolongation and the potentially fatal torsades de pointes (TdP) ventricular tachycardia to the labeling of droperidol (Inapsine - Akorn), an antiemetic used mostly in anesthesia. The Canadian Health Protection Branch has issued a similar warning. Some anesthesiologists have written to The Medical Letter to express their displeasure with these warnings.
Over-the-counter Omeprazole (Prilosec OTC)
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003 (Issue 1162)
).
SOME OTC DRUGS FOR HEARTBURN
Drug Dosage
1
Cost
2
H
2
-BLOCKERS
Cimetidine − average generic ...
The FDA recently approved the proton pump inhibitor omeprazole magnesium (Prilosec OTC) for over-the-counter use for treatment of frequent heartburn. It will be marketed in late September or early October. Five proton pump inhibitors, including omeprazole, are available by prescription in the US (Medical Letter 2001; 43:36).
Parcopa: A Rapidly Dissolving Formulation of Carbidopa/Levodopa
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005 (Issue 1201)
- and controlled-release tablets.
1
THE NEW FORMULATION — The orally dissolving
tablets can be taken ...
An orally dissolving, immediate-release tablet formulation of carbidopa/levodopa (Parcopa - Schwarz) that can be taken without water is now available for treatment of Parkinson's disease.
In Brief: Melamine
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
injury appeared to
be the cause.
1
Melamine (C
3
H
6
N
6
) is a heterocyclic compound, twothirds ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
In Brief: Plan B for 17-Year Olds
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
to the emergency contraceptive Plan B
1
from 18 to 17 years old. In a randomized, controlled trial, the two 0.75 ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
Bupivacaine Liposome Injection (Exparel) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Apr 02, 2012 (Issue 1387)
,
which cause fewer adverse effects.1,2
Local anesthetics such as bupivacaine are commonly
administered ...
The FDA has approved a new formulation (Exparel –
Pacira) of the local anesthetic bupivacaine (Marcaine,
and others) for use in the management of postsurgical
pain in adults.
Choice of Drug-Eluting Stents
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012 (Issue 1406)
stents (DESs) have
largely replaced bare-metal stents (BMSs).1
BARE-METAL STENTS — Intracoronary stents ...
The use of intracoronary stents in angioplasty procedures
has improved both short- and long-term success
rates. In recent years, drug-eluting stents (DESs) have
largely replaced bare-metal stents (BMSs).
Apremilast (Otezla) for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • May 26, 2014 (Issue 1443)
to 40% of patients
with psoriasis develop psoriatic arthritis.1 Nonsteroidal
anti-inflammatory drugs ...
Apremilast (Otezla – Celgene), an oral phosphodiesterase
type-4 (PDE4) inhibitor, has been approved
by the FDA for treatment of active psoriatic arthritis in
adults. It is the fi rst PDE4 inhibitor to be approved for this
indication.
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Nov 07, 2016 (Issue 1507)
of the protein dystrophin in
muscle cells. Dystrophin is essential for maintenance
of myocyte integrity.1 About ...
Eteplirsen (Exondys 51 – Sarepta), an antisense
oligonucleotide, has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in patients who have a mutation
of the dystrophin gene that is amenable to exon
51 skipping. It is the first drug to be approved for
treatment of DMD.